Examining “value” in the management of prostate cancer

Three new articles in the Journal of Oncology Practice take close look at the issue of risk/benefit and “value” in the management of prostate cancer today — and the management of advanced disease in particular. … READ MORE …

Effects of prazosin + radiation therapy on recurrence-free survival

The following was brought to our attention by Arthur as a consequence of a question posed on Ask Arthur by a reader within the past 24 hours. … READ MORE …

Three-year biochemical recurrence after Retzius-sparing RALP

Back in January this year we commented on a technique known as Retzius-sparing radical prostatectomy, which — according to its advocates — is said to facilitate recovery of erectile function post-surgery. … READ MORE …

Low-dose-rate brachytherapy monotherapy at the Mayo Clinic

A clinical research team from the Mayo Clinic (Routman et al.) has reported 10-year oncological results on 974 consecutive low- and intermediate-risk patients treated with low-dose-rate brachytherapy monotherapy (using iodine-125 seeds) from 1998 to 2013. … READ MORE …

Prostate cancer outcomes today vs. outcomes yesteryear

As some of us have long suspected and understood, using data from men treated 20+ years ago as a guide to what would happen if you were treated the same way today is not really a very good idea. … READ MORE …

Salvage radiation dose: decision-making under uncertainty

A large, well-done, confirmed, randomized clinical trial (RCT) is the only evidence that proves that one therapy is better than other. According to current consensus, this is deemed “Level 1a” evidence. But this high level of evidence is seldom available. … READ MORE …

ORP vs. RALP re-visited

A newly published report in The Lancet Oncology has pretty much finally confirmed what many of us have been assuming for a long time now: … READ MORE …